Cyclic AMP potentiates glucose-stimulated insulin release and mediates the stimulatory effects of hormones such as glucagon-like peptide 1 (GLP-1) on pancreatic ␤-cells. By inhibition of cAMP-degrading phosphodiesterase (PDE) and, in particular, selective inhibition of PDE3 activity, stimulatory effects on insulin secretion have been observed. Molecular and functional information on ␤-cell PDE3 is, however, scarce. To provide such information, we have studied the specific effects of the PDE3B isoform by adenovirus-mediated overexpression. In rat islets and rat insulinoma cells, approximate 10-fold overexpression of PDE3B was accompanied by a 6 -8-fold increase in membrane-associated PDE3B activity. The cAMP concentration was significantly lowered in transduced cells (INS-1(832/13)), and insulin secretion in response to stimulation with high glucose (11.1 mM) was reduced by 40% (islets) and 50% (INS-1). Further, the ability of GLP-1 (100 nM) to augment glucose-stimulated insulin secretion was inhibited by ϳ30% (islets) and 70% (INS-1). Accordingly, when stimulating with cAMP, a substantial decrease (65%) in exocytotic capacity was demonstrated in patch-clamped single ␤-cells. In untransduced insulinoma cells, application of the PDE3-selective inhibitor OPC3911 (10 M) was shown to increase glucose-stimulated insulin release as well as cAMP-enhanced exocytosis. The findings suggest a significant role of PDE3B as an important regulator of insulin secretory processes.
Increases in the intracellular content of cAMP promote insulin synthesis and secretion from the ␤-cells of pancreatic islets. Treatment with adenylyl cyclase activators, e.g. forskolin, results in a potentiation of glucose-induced insulin release (1) , as does stimulation with hormones and neurotransmitters known to act as stimulatory G-protein agonists (2) . An example of particular interest is glucagon-like peptide-1 (GLP-1), 1 one of the most potent enhancers of glucose-stimulated insulin secretion and in current focus for treatment of type 2 diabetes (3). The GLP-1 effect is seen in the presence of stimulatory concentrations of glucose and is exerted through cAMP-induced activation of protein kinase A (PKA) (3, 4) . Although this classic concept of cAMP/PKA signaling, leading to phosphorylation of protein substrates that regulate insulin release, still holds as the principal mechanism by which cAMP exerts its effects, apparent PKA-independent stimulation of ␤-cell exocytosis mediated by cAMP has also been observed (5) . In contrast to the involvement of cAMP in the insulin response to G-protein coupled-receptor agonist, it has not been established whether cAMP mediates glucose-stimulated insulin release. Such a function is supported by studies showing that cAMP levels are increased in ␤-cells stimulated with glucose (6, 7) . Other studies, however, indicate that glucosestimulated insulin release occurs efficiently regardless of ␤-cell PKA activity (8, 9) , and it has been suggested that even though cAMP can elicit insulin secretion it may not be necessary for glucose-stimulated insulin release. Therefore, the role of cAMP in glucose-stimulated insulin secretion remains to be established.
The cellular content of cyclic nucleotides is defined by the balance between activities of adenylyl cyclases and cyclic nucleotide phosphodiesterases (PDEs). PDEs catalyze the hydrolysis of cAMP and cGMP. The enhancing effect of general inhibitors of PDE, such as isobutylmethylxanthine, on glucosestimulated insulin release has been known for decades (10) and has contributed to the concept that cAMP and/or cGMP are functionally important in ␤-cells. Today, a complex pattern of interactions can be anticipated between different members of the large superfamily of PDE enzymes (PDE1-11) (11) and their substrates. PDE families are functionally diverse although structurally related; the carboxyl-terminal located catalytic domain is well conserved in all known PDEs, whereas the divergent amino-terminal portions form the basis for specific protein interactions and response to regulatory signals. The availability of family-selective PDE inhibitors has facilitated understanding of the roles of specific PDEs in different tissues. With the use of such inhibitors, activities belonging to, at least, PDE families 1, 3, and 4 have been recognized in ␤-cells (12) (13) (14) (15) (16) . The relative contribution of these PDEs to secretory events is not known, although in isolated rat islets inhibition of PDE1 (15) and PDE3 (12, 15) , and to a lesser extent inhibition of PDE4 (15) , has been reported to augment insulin release. Di-verging results have been obtained by use of insulinoma cells; in BRIN-BD11 cells, inhibition of PDE3 and 4, but not PDE1 (16) , and in ␤-TC3 cells inhibition of PDE4, but not PDE3 (15) , seems to stimulate insulin secretion. Data from in vivo experiments indicate that PDE3 inhibitors act as insulin secretagogues in rodents (13, 17) . Because use of selective PDE3 inhibitors has been discussed as a therapeutic approach for prevention or treatment of type 2 diabetes (18), it is important to elucidate the functional differences between PDE families in ␤-cells.
In the present study, we have aimed to elucidate the role of PDE3 in ␤-cell function. Two isoforms, PDE3A and -3B, are known. They are structurally closely related but are transcribed from different genes and are tissue-specifically expressed. Thus, whereas PDE3A is highly expressed in the cardiovascular system, PDE3B is expressed in cells important for energy metabolism, such as white and brown adipocytes and hepatocytes (19) . The presence of the PDE3B isoform has also been shown in neonatal rat pancreatic islets and HIT-T15, a hamster ␤-cell line (14) . To circumvent the ambiguity in results obtained using family-selective inhibitors, we have chosen to increase, specifically, the activity of PDE3B in ␤-cells. By employing adenovirus-mediated gene transfer, PDE3B was efficiently overexpressed, and the resulting, severalfold increased activity dramatically decreased insulin release. Notably, besides an evident suppression of cAMP-potentiated insulin secretion, an unexpectedly large decreasing effect on glucosestimulated insulin release was observed. Accordingly, using the patch-clamp technique, we were able to demonstrate a substantial decrease in cAMP-potentiated exocytosis in single ␤-cells overexpressing PDE3B.
EXPERIMENTAL PROCEDURES
Cell Culture-Rat insulinoma INS-1 (20) and INS-1(832/13) (21) cells (the latter an INS-1-derived clone modified through stable transfection with the human proinsulin gene) were used. Cells (INS-1 at passages 80 -100 and INS-1(832/13) at passages 40 -60) were grown at 37°C in a humidified atmosphere of 5% CO 2 /95% air. The culture medium was RPMI 1640 containing 11.1 mM glucose, supplemented with 10% fetal calf serum, 100 units/ml penicillin, 100 g/ml streptomycin, and 50 M ␤-mercaptoethanol. Cell culture media with additives were from Invitrogen.
Isolation of Rat Islets-Pancreatic islets were isolated from male Sprague-Dawley rats (B&K Universal, Stockholm) by a collagenase digestion technique modified after Lacy and Kostianovsky (22) . Briefly, a midline laparotomy was performed, and the common bile duct was cannulated and ligated at the papilla Vateri. The pancreas was filled with 10 ml of ice-cold Hanks' balanced salt solution (Sigma) supplemented with 1,3 units/ml collagenase P (Roche Molecular Biochemicals), removed, and incubated at 37°C for 20 min. Islets were handpicked under a stereomicroscope and incubated overnight in regular RPMI 1640. The next day the islets were equilibrated in Krebs-Ringer bicarbonate buffer (KRBB) consisting of 10 mM Hepes, pH 7.2-7.4, 120 mM NaCl, 5 mM NaHCO 3 , 5 mM KCl, 1.2 mM KH 2 PO 4 , 2.5 mM CaCl 2 , 1.2 mM MgSO 4 , and 0.2% bovine serum albumin, supplemented with 3 mM glucose, for 1 h.
Construction of Recombinant Adenoviruses-Control virus expressing ␤-galactosidase and adenoviral vectors was kindly provided by Drs. C. B. Newgard and H. Mulder. The procedure for generation of recombinant virus was as described by Becker et al. (23) . PDE3B-expressing virus (AdPDE3B) was constructed by XhoI digestion of pcDNA3.1/MPDE3B-FLAG (24) and subcloning of the entire fragment into the unique SalI restriction site of pACCMV.pLpA (25) . As packaging cell line, human embryonic kidney 293 cells were used. Recombinant adenoviruses were titrated using a plaque assay as described (23) . Clonal viral suspensions were amplified successively in 293 cells until high titers were obtained.
Adenovirus Infection and Cell Treatment-High titer adenoviral stocks (ϳ10 10 pfu/ml) were used to infect rat islets and rat insulinoma cells as indicated in the figure legends. Infection was performed for 16 h in regular RPMI culture medium containing 11.1 mM glucose. In experiments with insulinoma cells, medium was then substituted for KRBB, supplemented with 1-3 mM glucose, and incubated for 2 h. Buffer was changed and cells stimulated with glucose at various concentrations, in the absence or presence of GLP-1 (100 nM) for 60 min. After stimulation, aliquots of buffer were collected and stored at Ϫ20°C before measurement of the insulin concentration. Cells were harvested in a buffer consisting of 50 mM Tris-HCl, pH 7.4, 5 mM MgCl 2 , 1 mM EDTA, and 5% glycerol, supplemented with protease inhibitors 10 g/ml leupeptin, 10 g/ml antipain, and 1 g/ml pepstatin (Peptide Institute, Inc., Osaka, Japan). Cells were homogenized either by sonication or by passage through a syringe, and the homogenates were briefly centrifuged to remove cell debris. For cell fractionation, homogenates were centrifuged for 1 h at 100 000 ϫ g to recover membrane and cytosol fractions. Total protein amount was determined according to Bradford (26) .
When adenovirus-infected rat islets were studied, groups of 3 islets were distributed to 96-well plates and incubated in 200 l of KRBB containing glucose at the indicated concentrations, with or without addition of GLP-1 (100 nM), for 60 min at 37°C. Buffer was then withdrawn for determination of the amount of insulin secreted.
Selective Inhibition of PDE3-INS-1(832/13) cells were incubated in KRBB containing 1 mM glucose for 2 h, then stimulated with glucose in the presence of 10 M OPC3911 (Otsuka Pharmaceutical Co., Ltd, Tokyo, Japan) for 60 min.
Electrophysiology-Prior to patch-clamp experiments, INS-1(832/13) cells were maintained in tissue culture for up to two days in 35-mm plastic Nunc petri dishes. The dishes were used as experimental chambers with plastic inserts to reduce the volume to ϳ0.5 ml and were continuously perfused at a rate of 2 ml/min. Patch electrodes were made from borosilicate glass capillaries covered with Sylgard to their tips. Pipette resistances were 3-6 M⍀, and the zero-current potential of the pipette was adjusted in the bath. The experiments were performed with an EPC-7 patch-clamp amplifier using the software Pulse with the X-chart extension (version 8.4 and later; HEKA Elektronik, Lambrecht/ Pfalz, Germany). The holding potential was set to Ϫ70 mV to prevent activation of the endogenous voltage-gated Ca 2ϩ channels, except when desired. Exocytosis was detected as increases in cell capacitance by adding a 20-mV (peak to peak) sine wave of 500 Hz to the holding potential (Ϫ70 mV) and using either the X-chart extension or the sine ϩ dc mode of the lock-in amplifier (Fig. 6 , E and F), as described (27) . The extracellular solution consisted of 138 mM NaCl, 5.6 mM KCl, 1.2 mM MgCl 2 , 2.6 mM CaCl 2 , 5 mM D-glucose and 5 mM Hepes (pH 7.4 with NaOH). In Fig. 6 , E and F, an extracellular buffer was used with 20 mM NaCl replaced with equimolar tetraethylammonium-chloride to block outward voltage-activated K ϩ currents and a sub-maximal concentration (500 nM) of forskolin to raise cellular cAMP. OPC3911 (10 M) was added as indicated in the text and figures. In Figs. 5 and 6, A-D, exocytosis was elicited by intracellular dialysis of a Ca 2ϩ -containing pipette solution using the standard whole-cell configuration. The pipette solution contained 125 mM K-glutamate, 10 mM KCl, 10 mM NaCl, 1 mM MgCl 2 , 5 mM Hepes, 3 mM Mg-ATP, 10 mM EGTA, and 9 mM CaCl 2 (pH 7.15 with KOH), with an estimated free Ca 2ϩ concentration of 1.5 M using the binding constants of Martell and Smith (28) . This intracellular solution was also supplemented with cAMP (100 M) or the stable analogue Sp-cAMPS (50 M; Biolog, Bremen, Germany), as well as OPC3911 (10 M) as indicated. In Fig. 6 , E and F, exocytosis was evoked by activating the endogenous Ca 2ϩ channels with 500-ms voltage-clamp depolarizations from the holding potential (Ϫ70 mV) to zero. In these experiments, the cell interior was left virtually intact by establishing electrical contact using 0.24 mg/ml of the pore-forming antibiotic, Amphotericin B, (perforated patch whole-cell configuration; Ref. 29) added to the following pipette solution: 76 mM Cs 2 SO 4 , 10 mM CsCl, 10 mM NaCl, 1 mM MgCl 2 , 5 mM HEPES (pH 7.35 with CsOH). Unless otherwise stated, all compounds were from Sigma. In Figs. 5 and 6, A-D, rates of increases in cell capacitance were determined for the first minute after establishment of the standard whole-cell configuration, which exhibited excellent correlation with the total capacitance increase in extended recordings. In Fig. 6 , E and F, depolarizations were applied every 2 min, and the amplitude of the increases in cell capacitance was evaluated before and 6 min after addition of OPC3911. It was ascertained that the depolarization-stimulated capacitance increases remained stable for Ͼ10 min in the absence of OPC3911.
Reverse-transcription PCR-Total RNA was isolated using RNAzol B reagent (Tel-Test Inc., Friendswood, TX). Oligo(dT) 18 was used to prime one strand cDNA synthesis from 1 g of total RNA using the Advantage RT-for-PCR kit (Clontech, Palo Alto, CA). To amplify a fragment of PDE3A cDNA the sense primer CTGGCCAACCTTCAGGAATC was used in conjunction with the antisense primer CCCTCTTGGTTTC-CCTTTCTC (16) . For amplification of a fragment of rat PDE3B cDNA the sense primer CAGGAAGGATTCTCAGTCAG and antisense primer GTATTCTGGGCGAGAAAGAT (30) were used.
SDS-PAGE and Western
Blot Analysis-Isolated rat islets were washed and kept in a buffer consisting of 50 mM TES, 250 mM sucrose, 1 mM EDTA, and 0.1 mM EGTA, pH 7.4, supplemented with protease inhibitors as above. Homogenates from cells or islets were subjected to SDS-PAGE. Proteins were electrotransferred to polyvinylidene membranes (Millipore), and the membrane was blocked with 0.5% (v/w) gelatin in a buffer consisting of 20 mM Tris-HCl, pH 7.6, 137 mM NaCl, and 0.1% (v/w) Tween-20 for 60 min. Membranes were probed with polyclonal PDE3A or PDE3B antibodies for 16 h. The PDE3A antibody used was raised in rabbit using peptides corresponding to amino acids 1028 -1046 and 1019 -1141 of mouse PDE3A and the PDE3B antibody against the peptide CGYYGSGKMFRRPSLP from rat PDE3B sequence (30) . Antisera were affinity-purified using the peptides as affinity ligands. Proteins were detected using chemiluminescent Super Signal West Pico Luminol/Enhancer solution from Pierce and a Fuji LAS 1000 Plus system (Fuji Photo Film Co., Ltd, Tokyo, Japan).
Immunocytochemistry-PDE3B immunoreactivity in AdPDE3B-transduced and control Ad␤-gal-transduced INS-1(832/13) cells was investigated using the PDE3B antibody described above as primary antibody at 1:100 dilution and a secondary Cy5-conjugated anti-rabbit antibody (1:150 dilution, Jackson ImmunoResearch Laboratories). The Cy5 fluorophore was excited using the 633-nm line of a Zeiss LSM510 confocal microscope. Emitted light was collected using a ϫ100 oil objective and a Ͼ650-nm long pass filter. Images were taken using identical microscope settings and represent de novo scans (no previous photo-bleaching).
PDE Activity Measurements-PDE activity was measured in duplicate as described (31) in the presence or absence of 3 M OPC3911.
Assays were performed at 30°C in a total volume of 0.3 ml, containing 50 mM HEPES, pH 7.5, 0.1 mM EDTA, 8.3 mM MgCl 2 , and 0.5 M [ 3 H]cAMP (200 -500 cpm/pmol). Incubation times varied between 10 and 50 min, depending on protein concentration in samples.
Insulin Measurements-Insulin concentrations were determined in radioimmunoassays using commercial kit reagents, either from Diagnostic Products Corp., Los Angeles, CA (human insulin) or from Linco Research Inc., St. Charles, MO (rat insulin).
cAMP Measurements-The Biotrak cAMP assay system (Amersham Biosciences) was used according to instructions by the manufacturer.
Statistical Analysis-Data are quoted as mean values Ϯ S.E. of the indicated number of experiments. Statistical significance was evaluated using unpaired or paired Student's t test.
RESULTS
Expression of PDE3B in ␤-Cells-A previous report has shown that PDE3B is expressed in neonatal rat pancreatic islets (14) . In initial experiments, we confirmed this finding using homogenates of islets from adult rats (Fig. 1A) and rat insulinoma (INS-1) cells (Fig. 1B) . A single 135-kDa polypeptide, i.e. identical in size with the adipocyte form of PDE3B (32), was recognized. PDE3A could not be detected in Western blot analyses of these homogenates (data not shown). However, by employing reverse transcriptase-PCR using total RNA isolated from rat islets and INS-1 cells, the presence of mRNA encoding PDE3A is demonstrated in islets, whereas it is absent FIG. 1. PDE3 mRNA, protein, and activity in ␤-cells. RT-PCR, Western blot analysis, and PDE enzyme assays were used to demonstrate expression and activity of endogenous PDE3. Expression of PDE3B protein is shown in 50 rat islets (A) and INS-1 cells (100 g of total protein) (B). PDE3B solubilized from membranes of rat adipocytes was used as control (Ctrl). C, RT-PCR on total RNA from rat islets and INS-1 cells. For control, RNA from human smooth muscle cells (PDE3A) and rat adipocytes (PDE3B) were used as templates. D, total activity of PDE (white bars) and PDE3 activity (black bars) in membrane and cytosolic fractions of INS-1(832/13) cell homogenates is shown. The inset shows the PDE3B protein distribution in INS-1(832/ 13) homogenate (H), membrane (M), and cytosolic (C) fractions, with each lane containing 100 g of total protein. PDE3B solubilized from membranes of rat adipocytes was used as control (Ctrl).
in the INS-1 cells (Fig. 1C) . PDE3B mRNA is present both in islets and INS-1 cells. It is therefore likely that PDE3B is the major PDE3 isoform in ␤-cells and that islet non-␤-cells probably express PDE3A or both isoforms.
In contrast to adipocytes, in which PDE3B is the major PDE isoform (33), we have found that in rat islets ϳ30 -50% of the total PDE activity represents PDE3, whereas in homogenates of insulinoma cells the PDE3 activity has varied between 10 and 30% of total activity (data not shown). Typically, as seen in Fig. 1D , PDE3 activity comprises ϳ35% of total PDE activity in the membrane fraction of INS-1(832/13) cell homogenates. PDE3B protein and PDE3 activity appear solely in the particulate fraction (Fig. 1D) . This is in accordance with the known location of adipocyte PDE3B (33) .
Overexpression of PDE3B-To obtain efficient overexpression in primary ␤-cells, we employed adenovirus-mediated gene transfer. A recombinant adenovirus (AdPDE3B) housing mouse PDE3B cDNA was generated. In Western blot analyses of control rat islets and rat insulinoma cells infected with ␤-galactosidase-expressing virus (Ad␤-gal), PDE3B expression levels are comparable with non-treated cells (Fig. 2, A and B) . Islets and INS-1 cells transduced by AdPDE3B reveal a calculated 5-50-fold, dose-respondent (25-200 l of a high titer virus stock) increase in PDE3B expression (Fig. 2, A and B) . PDE3B immunoreactivity was also visualized in INS-1(832/13) cells by confocal microscopy, which convincingly demonstrated the overexpression in AdPDE3B-infected cells (Fig. 2C) . PDE3 activity was determined in islets and insulinoma cells infected with the lower amount of virus (25 l). The increased expression was followed by an ϳ5-10-fold elevated PDE3 activity in AdPDE3B-transduced, compared with control (Ad␤-gal-transduced), cells. Typical results, showing 8-(islets) or 6-fold (INS-1) increases, are visible in Fig. 2, D and E. Notably, in similarity to endogenously expressed PDE3B (Fig. 1D) , the activity of the virus-encoded protein does appear entirely in the particulate fraction of insulinoma cell homogenates (Fig. 2F) . These results show that recombinant PDE3B, expressed through adenoviral gene transfer, is correctly membrane-localized and enzymatically active. We have thus concluded that it is an appropriate model to study effects of enhanced PDE3B activity on important ␤-cell activities.
Effects of Overexpression of PDE3B on Glucose-stimulated Insulin Secretion-Previous work has indicated that inhibition of PDE3 activity does not affect basal insulin release from islets kept in non-stimulatory (3 mM) glucose concentration, although it enhances insulin release in the presence of high (8 mM) glucose (34) . We therefore initially examined, in static incubations, the effects of PDE3B overexpression on glucose-induced insulin secretion. Rat islets were infected with Ad␤-gal or AdPDE3B viruses and, following equlibration at low glucose, stimulated with 3 and 11.1 mM glucose, respectively, for 60 min. As seen in Fig. 3A , insulin released from control islets shows an approximate 25-fold increase in response to elevated glucose (44.3 Ϯ 1.4 and 1111.2 Ϯ 88.3 pg/h/islet at 3 and 11.1 mM, respectively; (n ϭ 15)), whereas in AdPDE3B-infected islets the increase is limited to ϳ15-fold (39.7 Ϯ 2.3 and 671.4 Ϯ 74.8 pg/h/islet at 3 and 11.1 mM, respectively; (n ϭ 15). We then performed similar experiments in insulinoma cells. INS-1 cells exhibit a lower secretory response to glucose than do islets, but in accordance with the reduction observed in islets, the increase in insulin secretion from 1.5 Ϯ 0.2 to 3.9 Ϯ 0.5 ng/h/10 6 cells (n ϭ 4) in Ad␤-gal-infected cells at high glucose is reduced to 2.1 Ϯ 0.2 ng/h/10 6 cells (n ϭ 4) in AdPDE3B-infected cells (Fig. 3B) . The reduction in insulin release of 40% in islets and 50% in INS-1 cells represents statistically significant differences (p Ͻ0.01). We next analyzed, in INS-1(832/13) cells, whether overexpression of PDE3B causes measurable changes in cAMP concentration. In Ad␤-gal-infected cells, the concentration of cAMP shows a 50% increase when glucose is raised from 3 to 11.1 mM (18.8 Ϯ 0.6 and 27.2 Ϯ 0.4 nmol/mg protein, respectively; n ϭ 3) (Fig. 3C) . Infection with AdPDE3B reduces the elevated cAMP concentration at 11.1 mM glucose by ϳ60% (27.2 Ϯ 0.4 (Ad␤-gal) and 12 Ϯ 2.7 nmol/mg protein (AdPDE3B); n ϭ 3)). We conclude that PDE3B, via reduction of cAMP, is capable of attenuating insulin secretion in response to glucose stimulation.
Effects of Overexpression of PDE3B on cAMP-potentiated Insulin Secretion-It is not known whether PDE family members in the ␤-cell act to degrade cAMP formed in response to any stimulating agent, as exemplified by glucagon, pituitary adenylate cyclase-activating polypeptide, and GLP-1, or rather whether there is a specific interaction between a certain cAMP pool and a specific phosphodiesterase. Because GLP-1 is a promising candidate for treatment of type 2 diabetes (3), we found it relevant to assess whether PDE3B is involved in the regulation of cAMP elevated by this hormone. Rat islets infected as above with control or AdPDE3B virus were stimulated with 11.1 mM glucose in the absence or presence of 100 nM GLP-1 for 60 min, followed by analysis of insulin release. In control islets, glucose-stimulated insulin secretion shows a 1.7-fold increase after stimulation with 100 nM GLP-1 (1111.2 Ϯ 88.3 and 1932.1 Ϯ 40.3 pg/h/islet, respectively; (n ϭ 14)) (Fig.  4A) . In islets overexpressing PDE3B, the stimulating effect of GLP-1 on insulin secretion is reduced by ϳ30% (to 1401.9 Ϯ 85.9 pg/h/islet; p Ͻ0.001; n ϭ 14). The above experiment was also performed in clonal ␤-cells. As seen in Fig. 4B , in INS-1 cells infected with Ad␤-gal, GLP-1 at 100 nM augments the glucose-induced insulin secretion by ϳ4-fold from 3.9 Ϯ 0.5 to 15.1 Ϯ 1.6 ng/h/10 6 cells (n ϭ 4), whereas infection with AdPDE3B results in a reduction of the potentiating effect of GLP-1 by ϳ70% (to 4.8 Ϯ 0.8 ng/h/10 6 cells); p Ͻ0.001; n ϭ 4). In accordance, cAMP levels increase 2-fold upon GLP-1 stimulation of control cells, whereas overexpression of PDE3B completely inhibits the GLP-1-mediated elevation of cAMP (Fig. 4C) .
Effect of Overexpression of PDE3B on cAMP-mediated Exocytosis-The suppression of insulin secretion by overexpression of PDE3B could result from a decrease in the number of responsive cells or, alternatively, by attenuating glucose/Ca 2ϩ -induced discharge of insulin-containing secretory granules in the single cell. To explore this latter possibility, we next performed patch-clamp experiments with single cell exocytosis monitored as increases in cell capacitance (Fig. 5 ). This method is based on the fact that the specific membrane capacitance is identical in the granular and plasma membranes (1F/m 2 ), such that the increase in cell surface area upon exocytosis can be detected as an increase in whole-cell membrane capacitance (each granule contributing ϳ2 femtofarad; Ref. 29 ). This method shows excellent correlation with other biochemical methods to detect single cell exocytosis (27) . In control (untransduced) INS-1(832/13) cells, exocytosis was readily initiated by establishing the standard whole-cell configuration (at t ϭ 0) and resultant intracellular dialysis of the Ca 2ϩ -(1.5 M free Ca 2ϩ ) and cAMP-containing pipette solution (Fig. 5A , upper black trace). The cell capacitance increased in a linear fashion at a rate of 30 femtofarad s Ϫ1 for ϳ2 min before reaching a plateau. In cells infected with AdPDE3B (lower gray trace), exocytosis was reduced by 65% (Fig. 5, A and B , p Ͻ0.01; n ϭ 10 and 4, untransduced and AdPDE3B-transduced cells, respectively). The difference in exocytotic capacity was already evident during the initial 60 s shown here. In fact, AdPDE3B infection completely counteracted the stimulatory action of cAMP on Ca 2ϩ -elicited exocytosis, and the observed exocytotic rates almost equalled those observed when cAMP was omitted from the intracellular solution (Fig. 5A, lower black trace) . By contrast, when the PDE-resistant cAMP analogue, Sp-cAMPS, substituted for normal cAMP (Fig. 5, C and D) , we failed to detect any difference in exocytotic capacity between Ad␤-gal and AdPDE3B-transduced cells (n ϭ 7 and 6, for untransduced and AdPDE3B-transduced cells, respectively). These results demonstrate that overexpression of PDE3B inhibits cAMPpotentiated Ca 2ϩ -elicited insulin exocytosis in the single ␤-cell. This action can be fully accounted for by increased PDE3B activity and is not due to an unspecific inhibitory action by AdPDE3B. 1-2) and adenovirusinfected rat islets (lanes 3-8) , each lane representing 50 islets. Titer of each viral stock was 1 ϫ 10 10 pfu/ml. 25 l/100 islets were used for Ad␤-gal infection (lanes 3-4) , and 25, 50, 100, and 200 l/100 islets were used for AdPDE3B-infection (lanes 5-8) insulin release in islets and different clonal ␤-cells. It appears, however, that selective inhibition of PDE3, for instance by milrinone (15) , Org 9935, SK&F 94836, and siguazodan (12, 16) , at micromolar concentrations augments glucose-stimulated insulin secretion in rat islets (12, 15) and rat-derived BRIN-BD11 cells (16) . Here, we decided to evaluate the effect of the PDE3-selective inhibitor OPC3911 on exocytosis of insulin granules in INS-1(832/13) cells (Fig. 6 ). Exocytosis was evoked using the standard whole-cell configuration and intracellular dialysis of a Ca 2ϩ -containing pipette solution (1.5 M free Ca 2ϩ ). In the presence of normal cAMP, inclusion of OPC3911 in the pipette (intracellular) solution accelerated exocytosis by Ͼ40% (p Ͻ0.001; n ϭ 15 and 17, in the absence and presence of OPC3911, respectively; Fig. 6, A and B) . By contrast, when Sp-cAMPS replaced normal cAMP in the pipette solution, the PDE3 inhibitor was without effect (n ϭ 8 and 7, without and with OPC3911, respectively; Fig. 6, C and D) .
Effect of a PDE3-selective Inhibitor on Exocytosis of Insulin-
We also investigated the effects of PDE3 inhibition on exocytosis in intact cells by using the perforated patch whole-cell configuration and eliciting exocytosis by 500-ms depolarizations that activate the Ca 2ϩ channels in the cell membrane. These experiments were made in the continued presence of a submaximal concentration of the adenylyl cyclase activator forskolin (500 nM) to elevate cytosolic cAMP from basal. Because putative cAMP gradients within the cell are unperturbed in intact cells, the potentiating action of PDE inhibitors on insulin release can be envisaged to be enhanced in this system. Indeed, 6 min after the addition of OPC3911, depolarizationevoked exocytosis was overall stimulated by ϳ220% from 37 Ϯ 4 to 82 Ϯ 8 femtofarad (Fig. 6, E and F ; p Ͻ0.01; n ϭ 6). Virtually identical results were obtained in mouse ␤-cells (200 Ϯ 41% stimulation; p Ͻ0.05; n ϭ 5; not shown). Depolarizationstimulated Ca 2ϩ entry was hardly affected (Fig. 6F, right panel) , indicating that, as in mouse ␤-cells (35) , the main action of cAMP is exerted on the level of the exocytotic machinery.
We then analyzed the effects of PDE3 inhibition on insulin release in static incubations of INS-1(832/13) cells stimulated with 11.1 mM glucose (Fig. 7) . In the presence of OPC3911 (10 M), insulin release was increased 1.7-fold (n ϭ 3), which agrees favorably with the suggestions that the PDE3 inhibitor stimulated insulin release more effectively in intact cellular systems.
DISCUSSION
The principal finding in this work is that increased PDE3B activity results in pronounced inhibitory effects on insulin secretory processes. The effects, as studied after overexpression of the enzyme, are apparent in isolated pancreatic islets as well as cultured insulinoma cells and derive from a decreased exocytotic capacity in the single cell. A remarkable reduction of insulin secreted in response to high glucose is observed. In a similar fashion, glucose-stimulated insulin secretion that is potentiated by elevated cAMP concentrations is suppressed.
PDE3B ectopically expressed from the recombinant adenovirus contributes to increased PDE3 activity in the transduced cells. This increase can either be explained solely by the greater amount of PDE3B protein per se or reflect, in addition, activation of the enzyme. Hormonal regulation of PDE3B activity has been extensively studied in adipose cells, in which insulin and isoproterenol activate the enzyme through phosphorylation of specific serine residues (32) . In HIT-T15 insulinoma cells, PDE3B is acutely activated in response to stimulation by IGF-I and leptin (14, 36 ) via a phosphatidylinositol 3-kinase-dependent pathway. The same authors also report that PDE3B is activated by GLP-1, although to a lesser extent. We have noted a similar activation by GLP-1 in INS-1 cells. The mechanism behind this is not completely understood, but it is likely to occur through elevated cAMP and subsequent activation of PKA, thus representing a feedback regulation of the cAMP pathway. Phosphorylation of PDE3B by PKA has been reported elsewhere (37) . We have also observed that PDE3B is activated by high glucose in rat islets and rat insulinoma cells. 2 Because in the present study clonal ␤-cells and islets are exposed to high glucose as well as cAMP, either directly supplied as in the single cell experiments or elevated by GLP-1 stimulation, it is conceivable that the increased PDE3B activity determined in AdPDE3B-infected cells is partially due to phosphorylation and activation by nutrients and hormones in the culture media.
The finding that overexpression of PDE3B, leading to increased PDE3 activity, has a significant impact on glucosestimulated insulin secretion brings forward the role of cAMP in nutrient-induced ␤-cell signaling. An early hypothesis proposed that cAMP is a prime mediator of glucose-stimulated insulin secretion (7, 38) . This hypothesis was supported by findings that glucose raises the islet content of cAMP (7, 39, 40) . However, compared with the cAMP-elevating capacity of, for example, nonspecific PDE inhibitors, glucose was found to be less effective in elevating cAMP although more efficient in releasing insulin. Because of such discrepancies between cAMP-promoting and insulin-releasing activities (39, 40) and the notion that cAMP merely synergizes with high glucose to enhance insulin secretion (e.g. Ref. 41) , the idea of an initializing role of cAMP in glucose-mediated insulin release was soon discarded. Instead, a prominent role of cAMP in amplifying glucose-induced insulin release was anticipated. However, such a role of cAMP for nutrient-induced insulin release has also been questioned, because inhibition of PKA activity by cAMP analogues (8) or pseudosubstrate for PKA (42) does not inhibit glucose-induced insulin secretion, although the same tools efficiently block secretion in response to adenylyl cyclase activators. It has also been shown that subcellular targeting of PKA by association with anchoring proteins is required for hormone-mediated insulin release but not for glucose-mediated secretion of insulin (43) . In contrast to these findings, our results obtained by overexpression of PDE3B, thus lowering the cAMP concentration in ␤-cells, demonstrate a clear detrimental effect on glucose-stimulated insulin secretion. Our data thus support the older idea that glucose may amplify its own action by elevating cAMP and are in line with data showing that cAMP deficiency in purified ␤-cells negatively influences nutrient-induced insulin release (44) , suggesting that a critical amount of cAMP may be required to preserve the full capacity of glucose. We therefore propose that cAMP has an important role in nutrient-induced insulin secretion as a potentiating feed-forward mechanism, increasing the efficacy of insulin release in a graded fashion related to elevations in extracellular glucose concentrations.
The cAMP-elevating effect of GLP-1 is well known and proposed to be the mechanism by which this hormone potentiates glucose-stimulated insulin secretion (45, 46) . It is not known, however, how cAMP formed as a result of GLP-1-mediated stimulation of adenylyl cyclase relates spatially or functionally to the isoforms of PDE that are present. To explain the simultaneous presence of different cAMP-degrading PDEs, it is believed that it is not only structural and kinetic differences between isoforms that are important but also their varying availability to regulators and substrates, because of their specific locations in the cell (47, 48) . It can be anticipated that co-localization at different compartments is achieved through multienzyme complexes in which, for example, specific PDEs and PKA isoforms are anchored together. Given that such arrangements exist, this may be the mechanism whereby cyclic nucleotides are degraded by specific PDEs. The observation that PDE3B decreases Ca 2ϩ -dependent exocytosis in INS-1(832/13) cells continuously dialyzed intracellularly with cAMP indicates the existence of a tight spatial association between PDE3B and the exocytotic machinery. Although decrease of cAMP is observed as a result of higher PDE3 activity in homogenates of AdPDE3B-infected cells (Figs. 3C and 4C ), under the particular conditions used in single cell experiments (Fig. 5 ) increased PDE3B activity is unlikely to affect significantly the overall cytosolic cAMP concentration, which remains close to that of the pipette solution (0.1 mM). This is because cAMP, not being a buffered molecule, will equilibrate rapidly in the cytosol. Given this, an increase in PDE3B activity can be expected to affect insulin exocytosis only if the phosphodiesterase operates in the immediate vicinity of the exocytotic machinery. The nature of this interaction is currently the subject of further investigations. It is therefore interesting to note that in the ␤-cells where PDE3B is overexpressed, cAMP formed in response to GLP-1 stimulation is available to and degraded by PDE3B. Detailed information on the localization of PDE3B in ␤-cells is not yet available. In primary rat adipose and liver cells PDE3B is predominantly found as a membrane-associated protein (33) ; its association to the membrane of the endoplasmic reticulum has been demonstrated in 3T3-L1 adipocytes (24) . The presence of PDE3 activity both in cytosolic and particulate fractions of rat islets has been reported (12) . We show here, however, that in control as well as AdPDE3B-infected insulinoma cells PDE3B activity can be measured solely in the particulate fraction. It is therefore possible that the cytosolic PDE3 activity found in islets represents non-membrane-bound splice variants of PDE3A in islet ␣Ϫ or ␦-cells. Such cytosolic forms of PDE3A have been identified in aortic smooth muscle cells, for example (48, 49) . There are no reports on the presence of PDE3A in ␤-cells. Using immunodetection, we have found no evidence for its expression in rat islets or clonal ␤-cells. However, mRNA encoding PDE3A could be detected in islets but not in INS-1 cells. This agrees with the report by Ahmad et al. (16) that mRNA encoding PDE3B but not PDE3A mRNA is present in clonal BRIN-BD11 cells and further supports the idea that PDE3A is expressed, perhaps at low levels, in islet cells other than ␤-cells.
In summary, we have utilized several ␤-cell models and methods to modulate the activity of the PDE3B isoform and have been able to demonstrate a substantial impact of this enzyme on cAMP-dependent exocytosis and secretion of insulin. The phosphodiesterase-mediated tight regulation of intracellular levels of cyclic nucleotides and the vital importance of these second messengers in many physiological aspects has drawn attention to PDE enzymes as targets for therapeutic intervention. Considering this, the tissue-specific expression of approximately 30 known isoforms and splice variants of PDEs accentuates the need for specific targeting of inhibitors and further detailed knowledge on isoform-related function.
